Remdesivir is the only antiviral approved for treatment of persons hospitalized for COVID-19. This supplement presents new information from real-world cohort studies reporting reduced mortality in at-risk populations and reductions in re-admission for COVID-19 in the Omicron era.

中文翻译：

---

瑞德西韦治疗 COVID-19 住院患者：Omicron 时代队列研究的有效性证据


瑞德西韦是唯一获准用于治疗 COVID-19 住院患者的抗病毒药物。该补充提供了来自真实世界队列研究的新信息，报告了在 Omicron 时代高危人群的死亡率降低和 COVID-19 再入院率的减少。